horiz (2)horiz (2)horiz (2)horiz (2)
  • Solutions
    • PepsinCheck
    • Reflux Band
    • Dx-pH System
    • Stretta
    • Secca
  • Clinicians
  • Patients
  • Blog
  • Events
  • Clinical Library
  • Login
✕
Survey Confirms Holiday Season Marks Higher Incidence Of Reflux Complaints
November 25, 2015
Stretta Therapy Acknowledges Esophageal Cancer Awareness Month
April 15, 2016

Stretta Therapy, a non-ablative radiofrequency treatment for GERD, was called “effective, safe and durable following 15 years of worldwide use” and cited as a “viable complement or alternative to medical and surgical treatment” in a newly-published clinical review of endoscopic techniques for gastroesophageal reflux disease (GERD). Authors Wai-Kit Lo, MD, MPH and Hiroshi Mashimo, MD, PhD of Harvard Medical School, examined multiple alternatives to PPI therapy or surgery, including Stretta and other devices such as endoscopic plication and suturing, as well as injectable and implantable bulking agents. Their findings have been published in the Journal of Clinical Gastroenterology.

ABOUT GERD AND ENDOSCOPIC TREATMENTS

GERD affects an estimated 20 percent of adults, and although PPI therapy is the accepted standard of care, there are approximately 40 percent of patients who still experience symptoms despite PPI treatment. The authors explain that the main anatomic and neuromuscular defects underlying GERD are not addressed by PPIs. They also recognize a rising awareness of adverse effects associated with long-term PPI use and a decline in the volume of surgical fundoplication, noting that these factors underscore the need for alternative approaches to complement medical and surgical treatments.

There are several endoscopic techniques available. However, recognizing that data about these therapies has been mixed, the authors undertook a critical assessment of these technologies to better understand the role that they play in the management of GERD symptoms.

THE WEALTH OF RESEARCH ON STRETTA

In their evaluation of treatments, authors noted that Stretta has the longest period of clinical evaluation, observing that Stretta data includes a meta-analysis of 1,441 patients across 18 studies, and four randomized-controlled trials. They referenced that Stretta earned the strongest grade recommendation by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) in guidelines forendoluminal treatment of GERD in 2013. They also reported that newer studies show that the effect of Stretta remains durable at eight and 10 years after initial therapy. Additionally, recent guidelines from the ASGE came out in support of a consideration of endoscopic treatments for GERD.

Regarding Stretta, the authors concluded that, “A wealth of research has demonstrated the safety, efficacy, durability, and repeatability of Stretta treatment. Most important, it does not preclude alternative treatments including medical, surgical, or repeat radiofrequency treatments, and may also provide potential treatment for patients who have failed fundoplication. Stretta is likely the least expensive alternative to medical therapy. This technique should be considered a viable complement or alternative to medical and surgical treatment of GERD symptoms.”

Share

Related posts

January 18, 2021

16 Million New Patients Covered for Stretta Therapy


Read more
November 19, 2020

Minimally Invasive Stretta Antireflux Procedure Accessible to Millions more Patients


Read more
October 6, 2018

Stretta Therapy Improves Quality of Life & Reduces PPI Dependency


Read more
New Study Confirms Stretta Therapy for GERD to be Safe, Effective and Durable
CONTACT

US: +800.352.1512
Int'l: +1 858.673.3700
Fax: 858.673.3783 contact@restech.com

Contact

Distributor Login
Clinician Login
Representative Login

How we Help

Solutions
PepsinCheck
Reflux Band
Restech
Stretta
Secca

About Us

Company
Contact Us
Job Opportunities
International Distributors
Compliance
Privacy Policy
Terms of Use

Follow Us

Respiratory Technology Corporation 11011 Brooklet Dr, Ste 300 Houston TX 77099 | © 2019 Restech. All Rights Reserved.
    FIND A DOCTOR
      Bree Gorman, VP Marketing

      Bree has been an integral part of Restech from the very beginning. She holds a Masters in Public Health from George Washington University, a BFA from The University of Kansas in Visual Communications, and is a National Board Certified Health & Wellness Coach. Her command of marketing, public health/health delivery systems, and human health behavior change gives her a unique perspective in developing effective marketing strategies for the company.  

      Physicians: Fill out the form below to complete your request to be added to the “Find-A-Doctor” map on restech.com

       


      Thomas Ball, PhD, VP Clinical Affairs

      Thomas previously worked as a polysomnographic technologist in the Virginia Mason system, before  moving into sales with Restech in 2007. After spending 9 years working with distributors across Europe, he was moved into an organizational role at the head office in Houston. In this capacity he works closely with sales and marketing to provide clinical support, manages clinical studies, and provides clinical perspectives on business development. In his spare time Thomas plays rugby for Houston Athletic Rugby Club.

      Jeff Klindworth, VP Business Development

      Jeff has over 30 years of experience in the medical device industry and previously worked in sales at companies such as Encision Inc., Interventional Therapies, LLC, Boston Scientific, and United States Surgical Corporation. He has been working as the VP of Sales for Mederi Therapeutics since 2009 and now brings his extensive expertise to Restech.  Jeff was part of the team that bridged the Mederi asset sale to Restech.  His clinical knowledge of the Stretta and Secca technologies is invaluable.  Jeff has three decades of physician relations experience that he brings to Restech as part of the leadership team.

      Ray Bengermino, VP Sales

      Ray joined Restech in May 2018 as the Vice President for Sales. He has been in the medical device, and specifically in the GERD space for more than 18 years. Starting in sales at Sandhill Scientific pH diagnostics, he moved on to Curon Medical when Stretta and Secca were first introduced to the market. He then worked for Given Imaging when Curon closed operations.  When Stretta was relaunced he joined Mederi as VP of Sales.  Ray was instrumental in keeping Stretta alive and the customer based informed when Mederi ceased operation and assets were purchased by Restech.  He is part of the leadership team directing all product sales for Restech. Ray graduated from Old Dominion University in Norfolk with a BS in Marketing and Business Administration.

      Mark Clark, CPA, CFO

      Mark is a seasoned professional and Certified Public Accountant in Texas who brings a unique blend of creative vision and financial expertise to any leadership team. He worked as a Senior Executive for 15 years on a leadership team which grew a private equity backed cash logistics company performing at negative EBITDA on $100 million revenue into an international industry leader with superior profitability on revenue exceeding $1.5 billion. In addition, he spent 10 years as a Senior Manager at Price Waterhouse delivering results-oriented merger & acquisition, audit and strategic consulting services to middle market clientele including over 40 manufacturing, distribution, service, nonprofit and technology clients. Mark currently serves as a Chief Financial Officer and consulting CFO (seven years) providing in-house and outsourced CFO and transactional services to the middle market.

      Larry Suarez

      Larry is the CTO for Restech and holds a B.S. in Computer Science. He is a software architect specializing in remote patient monitoring, medical sensors, and clinical trial software. Larry holds a patent on massively distributed computing and has worked for a number of major software startup companies including Sybase, Oracle, and Teradata.  Larry was also the co-founder of a startup to deliver advanced clinical pathways to patients using mobile devices and medical sensors. Larry is truly a pioneer and now a veteran in the deployment.

      Jeff Schipper

      Jeff has a breadth of experience with over 25 years in engineering and executive positions within major fortune 100 healthcare companies. He also has proven success in startup medical technology companies. Jeff provides leadership in securing and managing Restech’s patent portfolio. He also built Restech’s compliance platform that established regulatory acceptance in 25+ countries worldwide. Jeff’s scientific support and in-depth understanding of the device industry set the foundation for current and future commercial innovations at Restech.

      Leo Roucher

      With nearly 30 years of working with physician thought leaders developing novel and emerging technologies, Leo has played a key role in the development and evolution of balloon angioplasty and stent technologies that revolutionized the therapy of cardiac disease. His experience was instrumental in the development of the patented platform technology which drives the Restech sensor. Leo provides a vision and passion for effecting change in the diagnosis and management of atypical reflux.

      Deb Krahel

      With over 20 years of executive experience in both the private and public sector, Debra brings a broad understanding of healthcare delivery system. With experience managing products aimed at wide scale disease and population management for 20 million subscribers, Debra has extensive experience in effectively and efficiently developing models of delivery that address specific health issues. Debra has also been involved in the legislative process and served as the elected President of the Independent Physician Association of California. Debra is dedicated to bringing tools to the healthcare market that improve and support the clinical process.